Shanghai Bio-heart Biological Technology Co (HKSE:02185) Cash per Share : HK$1.21 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Shanghai Bio-heart Biological Technology Co Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Shanghai Bio-heart Biological Technology Co's Cash per Share for the quarter that ended in Jun. 2024 was HK$1.21.

Shanghai Bio-heart Biological Technology Co Cash per Share Historical Data

The historical data trend for Shanghai Bio-heart Biological Technology Co's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Bio-heart Biological Technology Co Cash per Share Chart

Shanghai Bio-heart Biological Technology Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash per Share

Get a 7-Day Free Trial

2.26

3.56

2.07

1.66

0.89

Shanghai Bio-heart Biological Technology Co Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash per Share	Get a 7-Day Free Trial						2.07	1.75	1.66	1.21	0.89

Shanghai Bio-heart Biological Technology Co Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Shanghai Bio-heart Biological Technology Co's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	404.083	/	243.42
	=	1.66

Shanghai Bio-heart Biological Technology Co's Cash per Share for the quarter that ended in Jun. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	293.789	/	243.42
	=	1.21

Shanghai Bio-heart Biological Technology Co (HKSE:02185) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Shanghai Bio-heart Biological Technology Co Cash per Share Related Terms

Thank you for viewing the detailed overview of Shanghai Bio-heart Biological Technology Co's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Bio-heart Biological Technology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Bio-heart Biological Technology Co Ltd (HKSE:02185) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.590 Ruiqing Road, Room 302, 3rd Floor, Building 4 & Building 6, East Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN

Website

http://www.bio-heart.com

Shanghai Bio-heart Biological Technology Co Ltd is engaged in the research and development of bioresorbable scaffold (BRS) products and the renal denervation (RDN) system. The company is a interventional cardiovascular device company in China, and locate in Shanghai Zhangjiang Hi-Tech Park Medical Device Industrial Park. Focused on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN), addressing the unmet medical needs of Chinese patients for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension.

Executives

Tpg Operating Group Ii, L.p.	2201 Interest of corporation controlled by you
Chen Hao	2201 Interest of corporation controlled by you
Zhu Linan	2201 Interest of corporation controlled by you
Wang Nengguang	2201 Interest of corporation controlled by you
Union Season Holdings Limited	2201 Interest of corporation controlled by you
Sk China Company Limited	2201 Interest of corporation controlled by you
Right Lane Limited	2201 Interest of corporation controlled by you
Proud Solar Limited	2201 Interest of corporation controlled by you
Magic Grace Limited	2101 Beneficial owner
Loft Success Investments Limited	2201 Interest of corporation controlled by you
Lc Healthcare Fund Ii, L.p.	2201 Interest of corporation controlled by you
Lc Healthcare Fund Ii Gp Limited	2201 Interest of corporation controlled by you
Lc Fund Gp Limited	2201 Interest of corporation controlled by you
Great Unity Fund I, L.p.	2201 Interest of corporation controlled by you
Lian Xiang Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you

Shanghai Bio-heart Biological Technology Co Headlines

No Headlines